Bonk (SHOT) Registration Filing summary

Company overview and business model

• Focuses on commercialization of the Sure Shot Dietary Supplement, designed to reduce blood alcohol content, with e-commerce and retail distribution including Amazon and BevMo!

• Owns intellectual property, trade secrets, and trademarks for its dietary supplement, and plans to expand into new product formats and flavors

• Discontinued legacy product lines to concentrate on dietary supplements, retaining a minority stake in a spun-off subsidiary

• Maintains a workforce of eight full-time employees and leverages partnerships with reputable raw material suppliers

• Outsources manufacturing to contract manufacturers in India and the US, with logistics handled by third-party warehouses and providers

Financial performance and metrics

• Raised $500,000 in September 2024 through a PIPE at $1.12 per share, a 10% discount to market

• Research and development expenses were $100,591 in 2022 and $1,637,117 in 2023

• As of September 24, 2024, 60,396,074 shares of common stock were outstanding, with 22,192,666 shares issuable upon exercise of outstanding warrants and options

Use of proceeds and capital allocation

• Proceeds from warrant and option exercises (up to $744,000 if fully exercised) will be used for research and development, patent and legal costs, and general working capital